e-learning
resources
Stockholm 2007
Monday 17.09.2007
Diagnostic markers and therapy in hospital-acquired pneumonia
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Strategies for de-escalation of therapy in patients with hospital-acquired pneumonia
P. Peyrani, A. Amir, M. F. Malinis, M. Cirino, R. Nakamatsu, J. A. Ramirez (Louisville, KY, United States Of America)
Source:
Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia
Session:
Diagnostic markers and therapy in hospital-acquired pneumonia
Session type:
Thematic Poster Session
Number:
2412
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Peyrani, A. Amir, M. F. Malinis, M. Cirino, R. Nakamatsu, J. A. Ramirez (Louisville, KY, United States Of America). Strategies for de-escalation of therapy in patients with hospital-acquired pneumonia. Eur Respir J 2007; 30: Suppl. 51, 2412
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia
Source: Eur Respir J 2011; 37: 1332-1339
Year: 2011
Trends in empiric antimicrobial therapy and efficiency of care for community-acquired pneumonia in hospitalized Belarussian patients
Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia
Year: 2007
Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia
Source: Eur Respir J 2010; 36: 128-134
Year: 2010
Hospital-acquired pneumonia in patients receiving immunosuppressive therapy
Source: Annual Congress 2009 - Treatment and prevention of lower respiratory tract infections
Year: 2009
Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia
Source: Eur Respir Rev 2007; 16: 33-39
Year: 2007
Efficacy and safety of stepwise therapy in patients with community-acquired pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 377s
Year: 2006
Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia
Source: Eur Respir Rev 2007; 16: 45-49
Year: 2007
Appropriateness and delay to initiate therapy in ventilator-associated pneumonia
Source: Eur Respir J 2006; 27: 158-164
Year: 2006
Influence of adherence to clinical guidelines in empiric antibiotics choice on outcomes of community-acquired pneumonia in hospitalized Belarussian patients
Source: Eur Respir J 2005; 26: Suppl. 49, 637s
Year: 2005
Effect of de-escalation antibiotic therapy on hospital-acquired, ventilator associated, and healthcare-associated pneumonia: A systematic review and meta-analysis
Source: International Congress 2016 – Severe respiratory infections in the intensive care unit and pleural and fungal infections
Year: 2016
Reducing antibiotics use for ventilator-associated pneumonia in brain-injured patients
Source: Eur Respir J 2016; 47: 1060-1061
Year: 2016
Aspiration risks factors, microbiology and empiric antibiotics for patients hospitalized with community-acquired pneumonia
Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice
Year: 2020
Ertapenem therapy for community-acquired pneumonia in the elderly
Source: Eur Respir J 2005; 26: Suppl. 49, 638s
Year: 2005
Impact of guidelines on HAP and VAP outcomes
Source: Eur Respir Mon 2011; 53: 66-73
Year: 2011
Adjunctive systemic corticosteroid treatment in hospitalized patients with community-acquired pneumonia
Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections
Year: 2012
Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP
Source: Eur Respir J 2013; 41: 123-130
Year: 2013
Empirical treatment of community-acquired pneumonia after outpatient beta-lactam therapy
Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Year: 2016
Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia
Source: Eur Respir J 2009; 33: 153-159
Year: 2009
Telithromycin is effective in the treatment of high-risk patients with community-acquired pneumonia
Source: Eur Respir J 2002; 20: Suppl. 38, 561s
Year: 2002
Diagnosis and treatment of nosocomial pneumonia in ALI/ARDS patients
Source: Eur Respir J 2003; 22: 77S-83S
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept